CAM
AUPH icon

Cresset Asset Management’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cresset Asset Management’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-13,000
Closed -$69K – 612
2019
Q3 		$69K Buy
+13,000
New +$78.7K ﹤0.01% 530

Other funds holding AUPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Cresset Asset Management's AUPH Position: Q4 2019 in Review

Cresset Asset Management sold out of Aurinia Pharmaceuticals (AUPH) in Q4 2019, closing a stake of 13,000 shares — an estimated $69K sold.

Cresset Asset Management first reported a position in AUPH in Q3 2019 and held it in 1 quarter. The position peaked at $69K in Q3 2019. 115 funds tracked by Wall St. Rank hold AUPH as of Q4 2019.

  • Cresset Asset Management reported no remaining Aurinia Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • Cresset Asset Management sold 13,000 Aurinia Pharmaceuticals shares in Q4 2019, an estimated $69K.
  • Cresset Asset Management first reported a position in Aurinia Pharmaceuticals in Q3 2019 and held it in 1 quarter.
  • Cresset Asset Management's Aurinia Pharmaceuticals position peaked at $69K in Q3 2019.
  • 115 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q4 2019.

Based on Cresset Asset Management's 13F filing for Q4 2019, filed 10 Feb 2020.